Skip to main content
. 2018 Mar 30;218(3):378–387. doi: 10.1093/infdis/jiy177

Figure 1.

Figure 1.

Participant flow through the study. See “Methods” for a description of vaccine formulations. DPX, DepoVax; RSV(A), respiratory syncytial virus subgroup A. aParticipants in the RSV(A)-Alum group received placebo on day 56, rather than RSV(A)-Alum. bOne subject was withdrawn by the investigators because of an adverse event.